This report covers the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report provides an overview of the current treatment options, pipeline products in development, as well as current and future R&D trends. Key topics covered include a strategic competitive assessment of current and future drugs, unmet needs, KOL insights, and implications for the Progressive Pulmonary Fibrosis market. The base year of the sales forecast model is 2025, and the forecast period is 2025-2035.
The progressive pulmonary fibrosis (PPF) therapeutics market totaled $1.3 billion in 2025 across the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK and Japan). It is projected to grow rapidly at an 8.4% compound annual growth rate (CAGR) to $2.9 billion by 2035, mainly driven by the entry of new disease-modifying therapies (DMTs) from the late-stage pipeline, the introduction of diversified combination regimens, and increased diagnosis rates. The US has the largest PPF market, accounting for approximately 80% of 7MM sales in 2025 and approximately 84% of 7MM sales in 2035 due to higher pricing, later generic erosion and faster uptake of novel therapies.
The progressive pulmonary fibrosis (PPF) therapeutics market totaled $1.3 billion in 2025 across the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK and Japan). It is projected to grow rapidly at an 8.4% compound annual growth rate (CAGR) to $2.9 billion by 2035, mainly driven by the entry of new disease-modifying therapies (DMTs) from the late-stage pipeline, the introduction of diversified combination regimens, and increased diagnosis rates. The US has the largest PPF market, accounting for approximately 80% of 7MM sales in 2025 and approximately 84% of 7MM sales in 2035 due to higher pricing, later generic erosion and faster uptake of novel therapies.
Report Scope
- Overview of PPF - including epidemiology, disease etiology and management.
- Topline PPF drugs market revenue, annual cost of therapy, and anticipated sales for major late-stage pipeline drugs.
- Key topics covered include assessment of marketed and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5EU, and Japan over the 10-year forecast period.
- Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global PPF therapeutics market. Insightful review of the key industry drivers and barriers.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the seven-market progressive pulmonary fibrosis (PPF) therapeutics market..
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact seven-market PPF market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the seven-market PPF therapeutics market from 2025-2035.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
1. Preface
3. Disease Overview
4. Epidemiology
5. Current Treatment Options
6. Unmet Needs and Opportunities
7. R&D Strategies
8. Pipeline Assessment
9. Market Outlook
10. Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Boehringer Ingleheim
- Bristol-Myers Squibb
- Avalyn Pharma
- United Therapeutics
- Insmed Inc
- Roche
- InterMune
- Brainomix
